coteau ARQ.

SCTX

Scribe Therapeutics Inc.
$15.41
−$2.55 (14.20%) Oct 23 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-29%+6%+40%+74%+109%Jul 27Oct 23Sep 952w high $39.6052w low $13.50
SCTXSPY
Wall St. Highest PT $60.00 (+289.4%) Wall St. Avg PT $57.00 (+269.9%)
$15$32$49$65$82POC $21Hi $60Avg $57
Underwater Drawdown %Max DD -58.6%Current -58.6%
0.0%-58.6%
Relative Strength vs SPY-21.8% vs SPYUnderperforming
+107%0%-107%
1W
−$4.67 (23.26%)
1M
−$11.12 (41.91%)
3M
–
6M
–
YTD
–
1Y
–

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Analyst price targets
Current price$15.41
Average target$57.00
+$41.59 (+269.9%) upsideaverage target vs current price
CurrentAverageMedian
Low$50.00
Median$57.00
High$60.00
12-month Wall Street target range
Recent analyst rating changes · 5
Reiterated
2026-09-03 · HC Wainwright & Co. reiterated Buy on SCTX
Initiated
2026-08-31 · HC Wainwright & Co. started covering SCTX at Buy
Initiated
2026-08-18 · Wells Fargo started covering SCTX at Overweight
Initiated
2026-08-18 · Leerink Partners started covering SCTX at Outperform
Initiated
2026-08-18 · Guggenheim started covering SCTX at Buy
All analyst rating changes ›

Third-party ratings, not Coteau's views.

Key stats & company

Market value$291.6M
P/E (next 12 months, estimated)-4.3
52-week range$13.50 – $39.60
Revenue growth (latest quarter vs a year ago)-60.8%
Dividend yieldNo dividend
Average analyst price target$57.00 (+270%)

What they do

Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for SCTX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 Coteau Physical AI Grid & Power
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

Earnings & events

SCTX earningsNext report in 17 days
Next report
Wed Nov 11, 2026Time not confirmed
EPS consensus-$1.03 range -$1.46–-$0.75
Revenue consensus$3.7M 5 analysts
Last 1 quarters · EPS vs estimate
Sep 2, 2026-$2.62est -$3.72+29.5%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-24 02:47:12 ET
26-09-3.720.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$1.9M–
2026-03-31$2.2M–
2025-06-30$4.9M–
2025-03-31$17.1M–

News & catalysts

More news
No recent headlines.
Rating changes
Reiterated
2026-09-03 · HC Wainwright & Co. reiterated Buy on SCTX
Initiated
2026-08-31 · HC Wainwright & Co. started covering SCTX at Buy
Initiated
2026-08-18 · Wells Fargo started covering SCTX at Overweight
Initiated
2026-08-18 · Leerink Partners started covering SCTX at Outperform
Initiated
2026-08-18 · Guggenheim started covering SCTX at Buy

Third-party analyst actions, not Coteau's views. All rating changes

Stats refreshed 2026-10-24 02:47:12 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, Coteau model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

coteau

Free to use. No card, no ads, no auto-renew.

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026